Eagle Pharmaceuticals, Inc.

OTCPK:EGRX Stock Report

Market Cap: US$11.0m

Eagle Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 4/6

Eagle Pharmaceuticals has a total shareholder equity of $252.0M and total debt of $70.2M, which brings its debt-to-equity ratio to 27.8%. Its total assets and total liabilities are $404.8M and $152.8M respectively. Eagle Pharmaceuticals's EBIT is $41.7M making its interest coverage ratio 7.2. It has cash and short-term investments of $15.4M.

Key information

27.8%

Debt to equity ratio

US$70.19m

Debt

Interest coverage ratio7.2x
CashUS$15.35m
EquityUS$252.04m
Total liabilitiesUS$152.78m
Total assetsUS$404.82m

Recent financial health updates

Recent updates

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Sep 21
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Jul 13
Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

Jun 21
Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Dec 16
Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Financial Position Analysis

Short Term Liabilities: EGRX's short term assets ($187.3M) exceed its short term liabilities ($86.6M).

Long Term Liabilities: EGRX's short term assets ($187.3M) exceed its long term liabilities ($66.2M).


Debt to Equity History and Analysis

Debt Level: EGRX's net debt to equity ratio (21.8%) is considered satisfactory.

Reducing Debt: EGRX's debt to equity ratio has increased from 25.2% to 27.8% over the past 5 years.

Debt Coverage: EGRX's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: EGRX's interest payments on its debt are well covered by EBIT (7.2x coverage).


Balance Sheet


Discover healthy companies